


Drugs@FDA: FDA-Approved Drugs

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=206494\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=206494)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA-APPROVED DRUGS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=206494\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA-APPROVED DRUGS&url=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=206494)



 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA-APPROVED DRUGS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=206494\)](mailto:?subject=Drugs@FDA: FDA-APPROVED DRUGS&body=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=206494)

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 206494

Company: ALLERGAN

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=206494\)](mailto:?subject=Drugs@FDA: FDA APPROVED DRUG PRODUCTS&body=http://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process%26varapplno=206494)

- [Summary Review \(http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000SumR.pdf\)](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000SumR.pdf)

Products on NDA 206494

[CSV](#)[Excel](#)[Print](#)

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status
 AVYCAZ	AVIBACTAM SODIUM; CEFTAZIDIME	EQ 0.5GM BASE;2GM/VIAL	POWDER;IV (INFUSION)	Prescription

Showing 1 to 1 of 1 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 206494



Labels for NDA 206494



